18F-FDG PET-CT显像在淋巴瘤疗效评价中的应用

 目的　研究PET-CT 对淋巴瘤治疗后评估的临床价值。方法　40 例经治疗的淋巴瘤患者行18F-FDG PET-CT显像，其中5例于治疗前后多次显像，评价其疗效，与临床疗效评价作对比。结果　5例患者行多次显像，其中2 例治疗后病灶消失，2例缓解，1例肿瘤复发，皆与临床相符。35例患者治疗后行PET-CT显像，30 例临床疗效为完全缓解和部分缓解的患者中，PET-CT显像阳性者25 例；5 例临床确认有肿瘤复发或明显残余，PET-CT显像均为阳性，PET-CT显像后改变了进一步临床治疗方案。结论　18F-FDG PET-CT显像能灵敏、准确地检出淋巴瘤复发及残余病灶，对疗效评价及指导临床治疗有重要价值。

18F-FDG PET-CT imaging for treatment evaluation in lymphoma

Objective To investigate the clinical value of PET-CT scans in lymphomatous patients in post-therapy evaluation. Methods 18F-FDG PET-CT imaging were performed in 40 lymphomatous patients whom had been received therapy. Successive PET-CT imaging were performed in 5 cases, and the treatment was evaluated with clinical evaluation. Results Successive PET-CT imaging were performed in 5 cases, in which the tumor was eradicated in 2 cases, improved in 2 cases, and relapsed in 1 case. In 35 patients PET-CT imaging was repeated after treatment, among them 30 cases with complete or partial remission, and PET-CT imaging was positive in 25 cases. PET-CT imaging was still positive in 8 cases with recurrent or remnant tumor. PET-CT imaging changed the therapeutic regime. Conclusion PET-CT imaging can detect the recurrent or remnant tumor sensitively and accurately. There is a significant value for the guidance of clinical therapeutic.